Fiasp - Another Insulin Aspart Formulation for Diabetes

Date: January 1, 2018 Issue #:  1537Summary:  The FDA has approvedFiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes.Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart(Novolog).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research